Physician profile
Christopher Gordon
NPI 1003234873
$5,625.30
in general payments reported to CMS, 2019-2025
21 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $466 · 2021: $479 · 2022: $917 · 2023: $893 · 2024: $1,112 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122 · Honoraria: $175 · Education: $53.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.36 |
| Honoraria | $175.00 |
| Education | $53.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,580.57 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,315.11 | 2019-2025 | |
| Amgen INC. | $427.89 | 2022-2025 | Tezspire |
| Aimmune Therapeutics, INC. | $416.42 | 2020-2024 | |
| Glaxosmithkline, LLC. | $390.84 | 2020-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $355.53 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $275.72 | 2020-2025 | Cuvitru, Takhzyro |
| Novartis Pharmaceuticals Corporation | $222.96 | 2019-2025 | |
| Csl Behring | $124.99 | 2019 | |
| Kaleo, INC. | $115.73 | 2021-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $81.45 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $60.57 | 2022-2025 | Orladeyo |
| Pfizer INC. | $51.35 | 2023-2025 | |
| Circassia INC. | $36.09 | 2021 | |
| Genentech, INC. | $35.80 | 2023 | Xolair |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.03 | 2020 | |
| Pharming Healthcare, INC. | $23.38 | 2024 | Ruconest |
| Lilly USA, LLC | $23.06 | 2025 | Ebglyss |
| Optinose US, INC. | $21.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.34 | 2021 | |
| Merck Sharp & Dohme LLC | $17.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.